---
schema_version: "secwatch.filing_event.v1"
accession: "0001006837-25-000002"
form_type: "8-K"
ticker: "VATE"
cik: "0001006837"
company_name: "INNOVATE Corp."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T21:47:10.292068+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MediBeacon TGFR System Receives FDA Approval for Kidney Function Assessment

## Summary
- FDA approved MediBeacon Transdermal GFR (tGFR) for assessing kidney function in adults with normal or impaired renal function without input of age, sex, race.
- TGFR uses a non-radioactive fluorescent agent (Lumitrace) with a transdermal sensor; no blood draws or urine analysis needed.
- Primary efficacy endpoint met: P30 value of 94% (95% CI: 89.4%-96.9%) in clinical study across GFR ranges and skin tones.
- More than 800 million people globally have chronic kidney disease; TGFR aims to improve point-of-care assessment.

## SEC filing metadata
- accession: 0001006837-25-000002
- form_type: 8-K
- ticker: VATE
- cik: 0001006837
- company_name: INNOVATE Corp.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/0001006837-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/hchc-20250117.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001006837-25-000002
- JSON: https://secwatch.observer/filing/0001006837-25-000002.json
- Plain text: https://secwatch.observer/filing/0001006837-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.